Key Developments: Amorfix Life Sciences Ltd (AMF.TO)

AMF.TO on Toronto Stock Exchange

0.04CAD
27 Mar 2015
Change (% chg)

$0.00 (+16.67%)
Prev Close
$0.03
Open
$0.03
Day's High
$0.04
Day's Low
$0.03
Volume
59,750
Avg. Vol
92,226
52-wk High
$0.45
52-wk Low
$0.03

Search Stocks

Latest Key Developments (Source: Significant Developments)

Amorfix Life Sciences Ltd closes private placement and receives back rights for ALS antibody therapeutic development
Tuesday, 21 Oct 2014 07:30am EDT 

Amorfix Life Sciences Ltd:Has closed the first tranche of a non-brokered private placement pursuant to which 1,260,000 common shares of Amorfix and 1,260,000 Warrants were issued for gross proceeds of C$352,800.The company intends to use the net proceeds of the Offering to continue the development of its research programs including its cancer therapeutic program, ProMIS and its Alzheimer's disease and for general corporate purposes.All securities issued in connection with the Offering are subject to a four month hold period from the date of issuance in accordance with applicable securities law.Also says it will get the rights back for development and commercialization of the ALS antibody therapeutics originally licensed to Biogen-Idec effective Jan. 14, 2015.  Full Article

Amorfix awarded broad United States patent for misfolded SOD1-targeted treatment of ALS
Wednesday, 16 Jul 2014 08:15am EDT 

Amorfix Life Sciences Ltd:Announces that company has been issued broad patent covering antibodies that target misfolded SOD1 (mSOD1) for treatment of ALS.Patent has issued as US 8,778,885.SOD1 is protein which is highly expressed in the motor nerve cells which degenerate in ALS.While normally protector of cells, under certain conditions it can misfold - its 3-dimensional structure becomes distorted - and it then becomes toxic for cells, as well as triggering propagated misfolding of normal SOD1.This mechanism of disease onset and progression supports mSOD1 as an attractive target for the development of novel therapeutics for the treatment of ALS.Amorfix's antibodies target misfolded SOD1 while sparing the normally folded proteins, and can neutralize the toxicity and block the propagation of misfolded SOD1.  Full Article

Amorfix Life Sciences Ltd appoints new chairman
Thursday, 12 Jun 2014 07:30am EDT 

Amorfix Life Sciences Ltd:Says William Wyman has been appointed chairman of the board.Neil Cashman, interim chairman, will remain as chief scientific officer and member of the board of directors.  Full Article

Amorfix Life Sciences Ltd closes private placement offering
Monday, 28 Apr 2014 07:00am EDT 

Amorfix Life Sciences Ltd:Closes third tranche of a non-brokered private placement pursuant to which 333,333 common shares of Amorfix (Shares) and 333,333 Warrants were issued for gross proceeds of C$100,000.Total number of Shares and Warrants that can be issued under the Offering is 3,800,000, for potential gross proceeds of $1,140,000.Intends to use proceeds to continue development of research programs including its cancer therapeutic program, ProMIS, its Alzheimer's disease and ALS diagnostic programs and for general corporate purposes.  Full Article

Amorfix Life Sciences Ltd closes private placement offering
Wednesday, 16 Apr 2014 11:32pm EDT 

Amorfix Life Sciences Ltd:Closes second tranche of non-brokered private placement pursuant to which 1,368,500 common shares of Amorfix and 1,368,500 warrants were issued for gross proceeds of C$410,550.Total number of shares and warrants that can be issued under offering is 3,800,000, for potential gross proceeds of C$1,140,000.Intends to use net proceeds of offering to continue development of its research programs including its cancer therapeutic program, ProMIS, its Alzheimer's disease and ALS diagnostic programs and for general corporate purposes.  Full Article

Amorfix Life Sciences Ltd closes private placement offering
Wednesday, 2 Apr 2014 11:11pm EDT 

Amorfix Life Sciences Ltd:Announces that it has closed the first tranche of a non-brokered private placement pursuant to which 1,618,500 common shares of Amorfix (Shares) and 1,618,500 Warrants were issued for gross proceeds of C$485,550.The total number of shares and Warrants that can be issued under the Offering is 3,800,000, for potential gross proceeds of $1,140,000.The company intends to use the net proceeds of the Offering to continue the development of its research programs including its cancer therapeutic program, ProMIS, its Alzheimer's disease and ALS diagnostic programs and for general corporate purposes.  Full Article

Amorfix Life Sciences Ltd and Trellis Bioscience to collaborate on anti-CD38 antibody treatment for cancer
Monday, 17 Mar 2014 08:00am EDT 

Amorfix Life Sciences Ltd:Enters into collaboration with Trellis Bioscience to develop antibodies against misfolded CD38 protein as treatment for haematological malignancies including leukemia and lymphoma.  Full Article

Amorfix Life Sciences Ltd closes private placement offering
Monday, 3 Mar 2014 07:00pm EST 

Amorfix Life Sciences Ltd:Says it has closed a non-brokered private placement.Says 1,600,000 common shares of Amorfix and 1,600,000 Warrants were issued for gross proceeds of C$448,000.Says it intends to use the net proceeds of the offering to continue the development of its research programs.  Full Article

Amorfix Life Sciences Ltd closes private placement offering
Wednesday, 15 Jan 2014 07:30am EST 

Amorfix Life Sciences Ltd:Says it has closed a non-brokered private placement (the offering).Says pursuant to which 1,000,000 common shares of Amorfix (Shares) and 1,000,000 Warrants were issued for gross proceeds of C$280,000.Says it intends to use the net proceeds of the Offering to continue the development of its research programs including its cancer therapeutic program, ProMIS, its Alzheimer's disease and ALS diagnostic programs and general corporate purposes.  Full Article

Amorfix Life Sciences Ltd Closes Private Placement Offering
Friday, 1 Nov 2013 08:04pm EDT 

Amorfix Life Sciences Ltd announced that it has closed a non-brokered private placement (the Offering) pursuant to which 400,000 common shares of Amorfix (Shares) and 400,000 Warrants were issued for gross proceeds of CAD112,000. The Company intends to use the net proceeds of the Offering to continue the development of its research programs including its cancer therapeutic program, ProMIS, its Alzheimer's disease and ALS diagnostic programs and for general corporate purposes including the completion of on-going discussions with multiple partners for a variety of business deals focused on the formation of strategic alliances and partnerships to advance the Company's therapeutic and diagnostic programs. Each Warrant entitles the holder to purchase one Share at a price of CDN$ 0.55 for a period of 24 months following the closing date of the Offering, subject to earlier expiry in the event (a trigger event) that, following the expiry of the four month hold period, the volume-weighted average price of Amorfix's common shares on the TorontoStock Exchange (TSX) over a period of twenty consecutive trading days exceeds $1.00. On the occurrence of a trigger event, Amorfix may give notice to holders to accelerate the expiry to a date which is not less than 30 calendar days after such notice is sent to the holders.  Full Article

No consensus analysis data available.
Search Stocks